目的 探討燈盞花素注射液聯(lián)合阿加曲班治療急性腦梗死的臨床效果。方法 選取2020年1月—2021年3月天津醫(yī)科大學(xué)寶坻臨床學(xué)院收治的90例急性腦梗死患者，隨機(jī)分成對(duì)照組和治療組，每組各45例。對(duì)照組靜脈滴注阿加曲班注射液，前2 d以60 mg/d的劑量靜脈泵入24 h，第3天以10 mg/次滴注，2次/d，1次/12 h，給藥時(shí)間3 h/次，連續(xù)治療5 d。治療組在對(duì)照組基礎(chǔ)上靜脈滴注燈盞花素注射液，20 mg加入250 mL 10%葡萄糖注射液，1次/d。兩組患者連續(xù)治療14 d。觀察兩組患者臨床療效，比較治療前后兩組患者美國(guó)國(guó)立衛(wèi)生研究院卒中量表（NIHSS）評(píng)分、血小板最大聚集率（MAR），血漿纖維蛋白原（FIB）和D-二聚體（D-D）水平，及血清金屬基質(zhì)蛋白酶-9（MMP-9）、內(nèi)皮素-1（ET-1）、單核細(xì)胞趨化蛋白-1（MCP-1）和白細(xì)胞介素-1β（IL-1β）水平。結(jié)果 治療后，治療組患者總有效率為91.1%，明顯高于對(duì)照組的75.6%（P<0.05）。治療后，兩組NIHSS評(píng)分均逐漸降低（P<0.05）。治療3、7、14 d后，治療組NIHSS評(píng)分顯著低于同期對(duì)照組（P<0.05）。治療后，兩組MAR和血漿FIB、D-D均顯著降低（P<0.05），且治療組明顯低于對(duì)照組（P<0.05）。治療后，兩組血清MMP-9、ET-1、MCP-1和IL-1β水平均顯著下降（P<0.05），且治療組降低更明顯（P<0.05）。結(jié)論 燈盞花素注射液聯(lián)合阿加曲班治療急性腦梗死的整體療效確切，可有效減輕患者神經(jīng)功能缺損。

Objective To investigate the clinical effect of Dengzhanhuasu Injection combined with argatroban in treatment of acute cerebral infarction. Methods Patients (90 cases) with acute cerebral infarction in Baodi Clinical Medical College of Tianjin Medical University from January 2020 to March 2021 were randomly divided into control and treatment groups, and each group had 45 cases. Patients in the control group were iv administered with Argatroban Injection, intravenously pumped with 60 mg/d for 24 h in the first 2 days, 10 mg/time for 3 h in the 3rd day, once every 12 h, they were treated for 5 d. Patients in the treatment group were iv administered with Dengzhanhuasu Injection on the basis of the control group, 20 mg added into 10% glucose injection 250 mL, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, the NIHSS, MAR, the concentrations of plasma FIB and D-D, and the levels of serum MMP-9, ET-1, MCP-1, and IL-1β in two groups before and after treatment were compared. Results After treatment, the clinical effective rate in the treatment group was 91.1%, which was significantly higher than 75.6% in the control group (P < 0.05). After treatment, NIHSS scores in both groups decreased gradually (P < 0.05). After 3, 7, and 14 days of treatment, the NIHSS score of the treatment group was significantly lower than that of the control group (P < 0.05). After treatment, MAR, plasma FIB and D-D concentrations in two groups were significantly decreased (P < 0.05), and which in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the levels of serum MMP-9, ET-1, MCP-1, and IL-1β in two groups were significantly decreased (P < 0.05), and the decrease was more obvious in the treatment group (P < 0.05). Conclusion Dengzhanhuasu Injection combined with argatroban is effective in treatment of acute cerebral infarction and can effectively reduce the neurological deficit of patients.

R971